Analyst Ratings February 6, 2026

Piper Sandler Lifts Align Technology Price Target to $220 After Q4 Beat

Strong Q4 results, margin improvement and case-volume gains prompt higher targets and upbeat analyst reactions

By Ajmal Hussain ALGN
Piper Sandler Lifts Align Technology Price Target to $220 After Q4 Beat
ALGN

Piper Sandler raised its price objective on Align Technology (ALGN) to $220 from $200 and kept an Overweight rating after the company posted fourth-quarter revenue and earnings that topped Street expectations. Align delivered $1,048 million in revenue, 5% year-over-year growth, and earnings per share of $3.29, ahead of the consensus estimate of $2.97. Management flagged initial 2026 guidance calling for mid-single-digit case volume growth and 3-4% revenue growth, which Piper Sandler characterized as reasonable.

Key Points

  • Piper Sandler raised its price target on Align Technology to $220 from $200 and maintained an Overweight rating.
  • Align reported Q4 revenue of $1,048 million (up 5% year over year) and EPS of $3.29, both above Street estimates, with margins beating analyst models.
  • Company guidance for 2026 targets mid-single-digit case volume growth and 3-4% revenue growth; Stifel also raised its price target to $210 and kept a Buy rating.

Piper Sandler has adjusted its valuation outlook for Align Technology (NASDAQ: ALGN), raising the firms price target to $220.00 from $200.00 while retaining an Overweight rating in the wake of the companys fourth-quarter results.

The new target sits near InvestingPros Fair Value assessment, which the research note says implies the stock is modestly undervalued at current levels. That assessment follows quarterly results in which Align reported revenue of $1,048 million for the fourth quarter - a 5% increase year over year and a beat versus the Street estimate of $1,033 million.

Revenue strength was broad-based, driven by balanced demand across both teen and adult aligner categories as well as scanner sales. Align posted earnings per share of $3.29 for the quarter, comfortably above the consensus EPS of $2.97. Analysts noted that margins also outperformed models, which supported the stronger-than-expected bottom-line performance.

Looking ahead, Piper Sandler characterized Aligns initial guidance for fiscal 2026 as reasonable. The companys outlook contemplates mid-single-digit growth in case volumes and revenue growth in the range of 3-4%. Piper Sandler argued that the conservative posture in guidance could allow for upside in quarterly results if current aligner demand trends persist.

Markets reacted quickly to the print. Aligns shares rose by roughly 12% in after-hours trading following the earnings release and accompanying analyst commentary, with Piper Sandler noting scope for further outperformance as management continues to deliver topline growth and tighter earnings control.


Additional analyst action tracked by the market also reflected the quarters upside. Align reported fourth-quarter 2025 earnings that beat expectations, with EPS of $3.29 versus the $2.97 consensus and revenue of $1.05 billion versus an anticipated $1.03 billion. The quarter featured a gross margin of 72.0%, noted as the companys highest since the first quarter of 2022, and a 7.7% increase in case volume, the strongest year-over-year case-volume growth since the fourth quarter of 2021.

In response to these results, Stifel raised its price target for Align Technology to $210 from $200 and kept its Buy rating, signaling a broader analyst re-evaluation following the strong operational and financial metrics.


Collectively, the beats on revenue and EPS, the improvement in gross margin, and the meaningful case-volume acceleration framed the recent analyst moves and the immediate market reaction. Aligns guidance approach and the companys ability to sustain current demand trends will be central to whether analysts and investors continue to push valuation assumptions higher.

Risks

  • If current aligner demand trends do not continue, the conservative 2026 guidance may not translate into positive quarterly outperformance - impacts the dental technology and healthcare markets.
  • Execution risk in sustaining elevated gross margins and delivering on mid-single-digit case volume growth could affect revenue and earnings outcomes - relevant to medical devices and dental technology sectors.
  • Short-term stock volatility is possible following large market reactions such as the approximately 12% after-hours move, which could affect equity investors and market sentiment in the healthcare equipment industry.

More from Analyst Ratings

Stifel Lowers JFrog Target Citing AI-Driven Security Concerns; Maintains Buy Rating Feb 22, 2026 HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026